Merck begins investigation into its handling of Vioxx

Share this article:
Directors at Merck are investigating the company's actions prior to its voluntary withdrawal of Vioxx from the market in September.
Merck's board of directors appointed a special committee comprised of seven members to closely examine the company's actions and respond to shareholder litigation, the company said in a statement yesterday.
William Bowen, president of The Andrew Mellon Foundation, will chair the special committee, which has hired the law firm Debevoise & Plimpton to conduct the review.
John Martin, a lawyer at Debevoise & Plimpton leading the inquiry, told the New York Times the committee wanted an independent examination of Merck's actions. Lawyers will review internal documents and interview company executives, he said.
"Our job is to conduct an investigation and not to defend the company," Martin told the Times.
Merck's chief executive, Raymond Gilmartin said the committee would have the "complete" cooperation of Merck management and full resources to make its assessment.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...